WO2017201200A8 - Compositions thérapeutiques contenant des antagonistes de rar-alpha - Google Patents

Compositions thérapeutiques contenant des antagonistes de rar-alpha Download PDF

Info

Publication number
WO2017201200A8
WO2017201200A8 PCT/US2017/033172 US2017033172W WO2017201200A8 WO 2017201200 A8 WO2017201200 A8 WO 2017201200A8 US 2017033172 W US2017033172 W US 2017033172W WO 2017201200 A8 WO2017201200 A8 WO 2017201200A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
therapeutic compositions
alpha antagonists
rar
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/033172
Other languages
English (en)
Other versions
WO2017201200A1 (fr
Inventor
Scott Mcnear THACHER
Paul Damian CROWE
Haiyan TAO
Raj Kumar Raheja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orphagen Pharmaceuticals Inc
Original Assignee
Orphagen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphagen Pharmaceuticals Inc filed Critical Orphagen Pharmaceuticals Inc
Publication of WO2017201200A1 publication Critical patent/WO2017201200A1/fr
Publication of WO2017201200A8 publication Critical patent/WO2017201200A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des procédés associés à l'utilisation d'antagonistes sélectifs du récepteur de l'acide rétinoïque (RAR), tels que des antagonistes sélectifs de RARα, pour une thérapie à agent unique ou une polythérapie du cancer, de tumeur ou de métastases tumorales.
PCT/US2017/033172 2016-05-19 2017-05-17 Compositions thérapeutiques contenant des antagonistes de rar-alpha Ceased WO2017201200A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338883P 2016-05-19 2016-05-19
US62/338,883 2016-05-19

Publications (2)

Publication Number Publication Date
WO2017201200A1 WO2017201200A1 (fr) 2017-11-23
WO2017201200A8 true WO2017201200A8 (fr) 2017-12-28

Family

ID=60325598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/033172 Ceased WO2017201200A1 (fr) 2016-05-19 2017-05-17 Compositions thérapeutiques contenant des antagonistes de rar-alpha

Country Status (1)

Country Link
WO (1) WO2017201200A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214575A1 (fr) * 2016-06-10 2017-12-14 Io Therapeutics, Inc. Composés rétinoïdes et rexinoïdes sélectifs du récepteur et modulateurs immunitaires pour l'immunothérapie du cancer
WO2019014468A1 (fr) * 2017-07-13 2019-01-17 Io Therapeutics, Inc. Sous-type de récepteur et composés rétinoïdes et rexinoïdes sélectifs d'une fonction en combinaison avec des modulateurs immunitaires pour l'immunothérapie anticancéreuse
US10363272B2 (en) 2017-08-31 2019-07-30 Io Therapeutics, Inc. RAR selective agonists in combination with immune modulators for cancer immunotherapy
US12492177B2 (en) 2019-12-19 2025-12-09 Orphagen Pharmaceuticals, Inc. RAR-α compounds for inflammatory disease and male contraception
US12115140B2 (en) 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma
JP7828661B2 (ja) * 2021-05-04 2026-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 避妊薬の化合物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245993C (zh) * 1997-03-11 2006-03-22 阿特纳赞塔里斯公司 用于治疗肿瘤的含有鲨鱼软骨提取物和抗肿瘤剂的药物组合物
TR201819157T4 (tr) * 2006-05-16 2019-01-21 Io Therapeutics Llc Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti

Also Published As

Publication number Publication date
WO2017201200A1 (fr) 2017-11-23

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2023010042A (es) Polinucleotidos moduladores.
WO2017201200A8 (fr) Compositions thérapeutiques contenant des antagonistes de rar-alpha
WO2018140831A3 (fr) Conjugués ciblant les tumeurs et leurs méthodes d'utilisation
NZ737399A (en) Ccr2 modulators
WO2016011222A3 (fr) Polynucléotides circulaires
WO2016100985A3 (fr) Récepteurs antigéniques chimériques et leurs procédés d'utilisation
SI3674298T1 (sl) Substituirani indazoli, postopek za njihovo pripravo, farmacevtske formulacije, ki jih vsebujejo, in njihova uporaba za pripravo zdravil
WO2015192127A3 (fr) Polypeptides d'un récepteur formulés dans une composition et procédés associés
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
WO2015118342A8 (fr) Composés aza bicycliques en tant qu'agonistes du récepteur muscarinique m1.
CL2015000337A1 (es) Compuestos derivados de 2,3-benzodiazepinas sustituidas; compuestos intermediarios; formulacion farmaceutica; uso para la profilaxis y/o terapia de trastornos tumorales tales como leucemias, carcinoma de prostata, carcinoma de mama, melanomas, entre otros y control de fertilidad masculina.
EP3273994A4 (fr) Thérapie à base de lymphocytes t car dirigés contre le récepteur lhr pour le traitement des tumeurs solides
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
TN2016000263A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
WO2016130581A8 (fr) Polythérapie anticancéreuse
WO2016138538A3 (fr) Utilisation thérapeutique d'anticorps de liaison à l'intégrine
WO2014035846A3 (fr) Composés azaindole substitué, leurs sels, leurs compositions pharmaceutiques et leurs procédés d'utilisation
EP3122381A4 (fr) Utilisation d'antagonistes de la kinase 1 apparentée au récepteur de l'activine (alk-1) dans le traitement du cancer
WO2014152809A3 (fr) Analogues de pparo et de 20-oh-pge2, et procédés d'utilisation de ceux-ci
WO2015143240A3 (fr) Compositions et procédés comprenant des 2- (acylamino) imidazoles
WO2016033549A3 (fr) Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
WO2017049140A3 (fr) Analogues d'angiotensine (1-7) et procédés associés
HK1237265A1 (en) Combination therapy compositions and methods for treating cancers

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17800116

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17800116

Country of ref document: EP

Kind code of ref document: A1